Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dTrSCfbwoceNfUwtmyJE

October 4, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • Bristol and Sanofi restructure sales alliance on 3 drugs
    Sanofi and Bristol-Myers Squibb revamped their marketing alliance for blood thinner Plavix, hypertension drug Avapro and a related drug named Avalide, in response to declining sales because of generic competition. The move would see Sanofi regain marketing rights to the three drugs in almost all countries, while Bristol would retain rights to sell Plavix in the U.S. through December 2019. Sanofi would pay Bristol royalties on worldwide sales of Avapro and Avalide and on sales of Plavix in all markets except the U.S. and Japan through 2018. Bristol would also receive $200 million at the end of 2018. Google/The Associated Press (10/3) LinkedInFacebookTwitterEmail this Story
Obesity Drugs: 'Useful Tools' With Lifestyle Modification
A good measuring stick for the likely acceptance and use of the two recently FDA-approved obesity drugs Qsymia (phentermine/topiramate) and Belviq (lorcaserin hydrochloride) came at Obesity 2012, the annual Obesity Society conference held in San Antonio recently. Find out the details.

  Health Care & Policy 
  • Barshefsky: TPP must protect biologics
    Trans-Pacific Partnership negotiations offer the U.S. an opportunity to support companies' ability to innovate, writes Charlene Barshefsky, a former U.S. trade representative. The agreement must include strong protections for intellectual property, especially involving biologics, she writes. The Wall Street Journal (10/2) LinkedInFacebookTwitterEmail this Story
 
  • Study shows efficacy of Janssen's Stelara for psoriasis
    A 52-week study found that Janssen Pharmaceuticals' Stelara, or ustekinumab, was effective and well tolerated in patients with moderate to severe plaque psoriasis. "These findings further advance our understanding of biologics, not just in terms of efficacy, safety and tolerability but also health-related quality of life," University of Munich professor Jorg Prinz said. Pharmaceutical Business Review Online (10/2) LinkedInFacebookTwitterEmail this Story
  • Celgene's Abraxane extends melanoma patients' survival in trial
    A Phase III trial showed that metastatic melanoma patients who received Celgene's breast cancer drug Abraxane survived longer without their disease worsening compared with those treated with chemotherapy dacarbazine. Celgene aims to expand approval of Abraxane to include other kinds of cancer, including melanoma and pancreatic cancer. Reuters (10/2) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Alimera raises $40M for diabetic macular edema delivery
    Alimera Sciences secured $40 million in a round of private placement with new and existing institutional investors. The firm will use the proceeds to launch its Iluvien drug delivery system for chronic diabetic macular edema in Germany, France and the U.K. MedCityNews.com (10/3) LinkedInFacebookTwitterEmail this Story
  • NIAID grants AvidBiotics $600K for antibacterial proteins
    The NIH's National Institute of Allergy and Infectious Diseases awarded AvidBiotics a two-year grant worth $600,000 to advance development of the firm's Avidocin bactericidal proteins to prevent the spread of Clostridium difficile. "This new funding will help support our preclinical research and advance Avidocin proteins towards the clinic," CEO David Martin said. Pharmaceutical Business Review Online (10/3) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  • Theravance, Alfa Wassermann agree to co-develop gastroparesis drug
    Alfa Wassermann and Theravance agreed to collaborate on midstage clinical development of the latter's experimental gastroparesis drug velusetrag. Wasserman will fund the trials and in exchange, will get the option to commercialize the drug in selected markets including the EU, Japan and Canada. If it exercises that option, Wasserman would pay $10 million plus as much as $53.5 million in milestone fees and sales royalties. CBS News/The Associated Press (10/2) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • German agency criticizes French health study of biotech corn
    The German Federal Institute for Risk Assessment has cited flaws in the design and data presentation of a French study that reported rats fed diets of a biotech corn were at risk of cancer and premature death. The study didn't meet internationally recognized standards for carcinogenicity research and used too few animals, the institute said. "This means that the conclusions drawn by the authors are not supported by the available data," said Reiner Wittkowski, the institute's vice president. FoodNavigator (10/3) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
I start with the premise that the function of leadership is to produce more leaders, not more followers."
--Ralph Nader,
American political activist, author, lecturer and attorney


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information